poly-vi-flor with iron- multivitamin and fluoride supplement suspension/ drops
aytu therapeutics, llc - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, d- (unii: a7e6112e4n) (.alpha.-tocopherol, d- - unii:n9pr3490h9), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - unii:8s95dh25xc), ferric citrate anhydrous (unii: 63g354m39z) (ferric cation - unii:91o4lml611), sodium fluoride (unii: 8zyq1474w7) (fluori - cholecalciferol 400 [iu] in 50 ml - fill the dropper to the 1 ml line to provide the full daily dosage. use full dosage, regardless of age or weight, unless your child's doctor recommends a different dosage. dispense with a single squeeze of the dropper bulb. it is normal for a small amount to remain in the tip. drops may be given by dispensing directly into the mouth. drops may also be mixed with formula, fruit juice, cereal or other foods to increase your child's acceptance.
poly-vi-flor- multivitamin and fluoride supplement suspension/ drops
aytu therapeutics, llc - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, d- (unii: a7e6112e4n) (.alpha.-tocopherol, d- - unii:n9pr3490h9), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - u - cholecalciferol 400 [iu] in 50 ml - fill the dropper to the 1 ml line to provide the full daily dosage. use full dosage, regardless of age or weight, unless your child's doctor recommends a different dosage. dispense with a single squeeze. drops may be given by dispensing directly into the mouth. drops may also be mixed with formula, fruit juice, cereal or other foods to increase your child's acceptance.
folgard- cholecalciferol, riboflavin, pyridoxine, folic acid, cyanocobalamin, calcium, and phosphorus tablet
upsher-smith laboratories, inc. - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium (unii: sy7q814vup) (calcium - unii:sy7q814vup), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w) - cholecalciferol 2000 [iu]
teva-alendronate/cholecalciferol tablet
teva canada limited - alendronic acid (alendronate sodium); vitamin d3 (cholecalciferol) - tablet - 70mg; 2800unit - alendronic acid (alendronate sodium) 70mg; vitamin d3 (cholecalciferol) 2800unit - vitamin d
teva-alendronate/cholecalciferol tablet
teva canada limited - alendronic acid (alendronate sodium); vitamin d3 (cholecalciferol) - tablet - 70mg; 5600unit - alendronic acid (alendronate sodium) 70mg; vitamin d3 (cholecalciferol) 5600unit - vitamin d
cholecalciferol pharmacare 10,000 iu soft capsules
pharmacare srl via marghera, 29 20149, milan, italy - soft capsule - colecalciferol 10000 iu - vitamins
cholecalciferol pharmacare 25,000 iu soft capsules
pharmacare srl via marghera, 29 20149, milan, italy - soft capsule - colecalciferol 25000 iu - vitamins
cholecalciferol
basf australia ltd. - cholecalciferol - unknown - cholecalciferol vitamin-d3 active 0.0 - active constituent
fosamax plus d- alendronate sodium and cholecalciferol tablet
physicians total care, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alendronic acid 70 mg - fosamax® plus d is indicated for: for the treatment of osteoporosis, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). fosamax plus d alone should not be used to treat vitamin d deficiency. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. the optimal duration of use has not been determined. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see warnings and precautions (5.1)] - inability to stand or sit upright for at least 30 minutes [see dosage and administration (2.3), warnings and precautions (5.1)] - hypocalcemia [see warnings and precautions (5.2)] - hypersensitivity to any component of this product. hypersensitivity reactions including urticaria and angioedema have
fosamax plus d- alendronate sodium and cholecalciferol tablet
merck sharp & dohme corp. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alendronic acid 70 mg - fosamax® plus d is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax plus d is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.2)]. fosamax plus d alone should not be used to treat vitamin d deficiency. the optimal duration of use has not been determined. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. fosamax plus d is contraindicated in